Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage ...
In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Biogen Inc. (BIIB), which belongs to the Zacks ...
The stock's fall snapped a five-day winning streak.
Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback